This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Targeted Thorium Conjugate, Thorium-277 Antibody Conjugate, TTC
Description: The thorium-227 antibody conjugate links thorium-227 to a tumor-targeting monoclonal antibody in order to deliver high-energy alpha particles directly to cancer cells. Bayer is investigating a Targeted Thorium Conjugate (TTC), comprising an anti-CD33 monoclonal antibody conjugated to a chelator for the efficient delivery of high-energy alpha-particles.
Deal Structure: In April 2011, Algeta announced that it entered a research collaboration with Genzyme to evaluate the potential of its Thorium platform. Under the terms of the collaboration, Genzyme will provide access to a novel and proprietary tumor-targeting antibody, and Algeta will provide access to its Thorium platform to attach the alpha emitting payload thorium-227. Both companies will contribute resources towards the collaboration, which is expected to last for up to a year initially.
In April 2012, the collaboration was extended for an additional year.
Bayer and Algeta
In December 2013, Bayer announced that it plans to strengthen its oncology portfolio with the acquisition of Algeta. Bayer has reached an agreement with Algetas Board of Directors to make a recommended voluntary public takeover offer to Algetas shareholders, and is offering them NOK 362 per share in cash. The offer implies an equity value of NOK 17.6 bn (EUR 2.1 bn) (USD 2.9 billion) and an enterprise...See full deal structure in Biomedtracker
227Th-Anti-CD33 Conjugate News
Pink Sheet Weekly Trademark Review September 10, 2013
Pink Sheet Weekly Trademark Review August 14, 2012
Additional information available to subscribers only: